VC-backed Edge Therapeutics goes public

By Iris Dorbian — 4 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has debuted its IPO after pricing its over 7.3 million shares at $11 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “EDGE.” Leerink Partners and Credit Suisse are serving as the lead underwriters. Edge Therapeutics’ backers included Venrock, Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures.

Continue

Regenxbio racks up $70.5 mln Series D

By Iris Dorbian — 9 months ago

Rockville, Maryland-based Regenxbio, a gene therapy-focused biotech company, has closed $70.5 million in Series D funding. Vivo Capital, Venrock and Brookside Capital led the round with participation from other investors that included Janus Capital Management LLC, Perceptive Advisors LLC, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management LLC, Foresite Capital Management, Deerfield Management and Fidelity Biosciences. Chardan Capital Markets LLC was the placement agent.

Continue

Edge Therapeutics racks up about $72.5 mln

By Iris Dorbian — 10 months ago

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

Continue

Aduro Biotech nets $51.4 mln Series D

By Iris Dorbian — 1 year ago

Berkeley, Calif.-based immuno-oncology firm Aduro Biotech has received $51.4 million in Series D financing. The investors included OrbiMed, Janus Capital Management, Franklin Advisers and Foresite Capital Management. Leerink Partners served as placement agent.

Continue

Apptio Raises $45M From Janus, Hillman, Andreessen, Madrona, Others: CORRECTION

By Mark Boslet — 3 years ago

Apptio said it raised a $45 million Series E round of funding led by Janus Capital, the Hillman Company and an unnamed institutional investor. The round was joined by existing investors Andreessen Horowitz, Greylock Partners, Madrona Venture Group, Shasta Ventures, and accounts managed by T. Rowe Price Associates. The new round brings the total raised to $136 million.

Continue